Edition:
United States

Intellipharmaceutics International Inc (IPCI.OQ)

IPCI.OQ on NASDAQ Stock Exchange Capital Market

0.22USD
3:59pm EST
Change (% chg)

$0.01 (+4.04%)
Prev Close
$0.21
Open
$0.21
Day's High
$0.24
Day's Low
$0.20
Volume
131,782
Avg. Vol
159,102
52-wk High
$10.40
52-wk Low
$0.20

Latest Key Developments (Source: Significant Developments)

Intellipharmaceutics Announces FDA Final Approval Of Generic Effexor XR
Tuesday, 27 Nov 2018 05:52pm EST 

Nov 27 (Reuters) - Intellipharmaceutics International Inc ::INTELLIPHARMACEUTICS ANNOUNCES FDA FINAL APPROVAL OF GENERIC EFFEXOR XR.INTELLIPHARMACEUTICS INTERNATIONAL- APPROVED PRODUCT IS GENERIC EQUIVALENT OF BRANDED PRODUCT EFFEXOR XR SOLD IN THE U.S. BY WYETH PHARMACEUTICALS.  Full Article

Intellipharmaceutics International Received Letter From Nasdaq To Delist Co's Securities
Monday, 23 Apr 2018 05:24pm EDT 

April 23 (Reuters) - Intellipharmaceutics International Inc ::INTELLIPHARMACEUTICS INTERNATIONAL SAYS RECEIVED LETTER FROM NASDAQ TO DELIST THE COMPANY’S SECURITIES FROM NASDAQ - SEC FILING.  Full Article

Intellipharmaceutics Announces Us$ 1.8 mln Registered Direct Offering‍​
Monday, 19 Mar 2018 03:10pm EDT 

March 19 (Reuters) - Intellipharmaceutics International Inc ::INTELLIPHARMACEUTICS ANNOUNCES US$ 1.8 MILLION REGISTERED DIRECT OFFERING‍​.INTELLIPHARMACEUTICS INTERNATIONAL-OFFERING OF 3 MILLION COMMON SHARES AT PURCHASE PRICE OF US$0.60 PER SHARE IN A REGISTERED DIRECT OFFERING - SEC FILING‍​.INTELLIPHARMACEUTICS INTERNATIONAL- THE OFFERING IS IN ADDITION TO OFFERING FOR GROSS PROCEEDS OF ABOUT US$3.5 MILLION WHICH WAS PREVIOUSLY ANNOUNCED.  Full Article

‍Armistice Capital​ Reports 5.2 Pct Passive Stake In Intellipharmaceutics International
Monday, 4 Dec 2017 05:34pm EST 

Dec 4 (Reuters) - Intellipharmaceutics International Inc ::‍ARMISTICE CAPITAL LLC​ REPORTS A 5.2 PERCENT PASSIVE STAKE IN INTELLIPHARMACEUTICS INTERNATIONAL INC AS OF NOV 22 - SEC FILING.  Full Article

Intellipharmaceutics launches additional strengths of generic Focalin XR in U.S.​
Thursday, 30 Nov 2017 10:44am EST 

Nov 30 (Reuters) - Intellipharmaceutics International Inc ::SAYS ‍LAUNCHED 5&40 MG STRENGTHS OF ITS GENERIC FOCALIN XR CAPSULES IN U.S​.SAYS UNDER DEAL BETWEEN CO & PAR, CO RECEIVES QTRLY PROFIT-SHARE PAYMENTS ON PAR'S U.S. SALES OF GENERIC FOCALIN XR.  Full Article

Intellipharmaceutics announces US$4 mln registered direct offering
Wednesday, 11 Oct 2017 08:00am EDT 

Oct 11 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics announces US$4 million registered direct offering.Intellipharmaceutics - ‍entered securities purchase agreements with investors providing for purchase ,sale of 3.6 million shares at US$1.10 per share​.  Full Article

Intellipharmaceutics- Q3 loss per share $0.08
Tuesday, 10 Oct 2017 05:20pm EDT 

Oct 10 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics announces third quarter 2017 results.Q3 loss per share $0.08.Q3 revenue $1.2 million versus $600,000.Intellipharmaceutics International Inc - ‍ expects revenue from generic Seroquel XR to increase going forward​.  Full Article

FDA Staff raises concerns about Intellipharma's opioid painkiller
Monday, 24 Jul 2017 10:49am EDT 

July 24 (Reuters) - Intellipharmaceutics International Inc -:FDA Staff: no new safety signals were identified with Intellipharma's opioid painkiller Rexista beyond what is already known for oxycodone products.FDA Staff: Intellipharma's opioid painkiller Rexista tablets are relatively easier to reduce into fine particles than OxyContin tablets.FDA Staff: most solvents had similar or lower extraction recoveries from Rexista tablets than from OxyContin tablets.FDA Staff: at the correct combination of testing conditions, Rexista tablet samples were similar or less syringeable than OxyContin .FDA Staff: not easy to separate/eliminate blue dye & nasal irritant in Rexista, without using extensive chemistry knowledge.FDA Staff: using complex extraction procedures, oxycodone base can be achieved with similar or lower purity & yield from Rexista than from OxyContin .FDA Staff: varying extent of physical manipulations progressively increase the oxycodone dissolution rate from both Rexista and OxyContin .FDA Staff: even with the largest extent of manipulation, Rexista still retained some extended-release characteristics.FDA Staff: Rexista tablets are less efficient to vaporize than OxyContin tablets.FDA Staff: There were no human abuse liability studies submitted with the marketing application for Rexista.FDA Staff: Safety info collected in Rexista pharmacokinetic studies was of limited value since these were generally single-dose studies.  Full Article

Intellipharma says Par Pharma launches additional strengths of generic Focalin
Wednesday, 24 May 2017 04:05pm EDT 

May 24 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics reports on launch of additional strengths of generic focalin xr® by par pharmaceutical.Intellipharmaceutics - par pharmaceutical has launched 10 and 20 mg strengths of its generic focalin xr capsules in u.s.Intellipharmaceutics international inc says expects remaining 5 and 40 mg strengths to be launched in near future.Intellipharmaceutics -under a licensing and commercialization , co receives quarterly profit-share payments on par's u.s. Sales of generic focalin xr.  Full Article